Business
Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins
- Initiates studies in collaboration with pediatric brain cancer expert, Dr. Eric Raabe, M.D., Ph.D - Collaboration will leverage Dr. Raabe's large panel of
About this update from Lantern Pharma Inc.
[{"type":"text","content":"- Initiates studies in collaboration with pediatric brain cancer expert, Dr. Eric Raabe, M.D., Ph.D\n - Collaboration will leverage Dr. Raabe's large panel of brain cancer cell lines and xenografts\n - ATRT may qualify under the Rare Pediatric Disease Designation which Lantern will pursue\n\n\nDALLAS, April 1, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"A.I.\") platform to transform oncology drug discovery and development, today announced a collaboration with Johns Hopkins Pediatric Oncology Division of The Sidney Kimmel Comprehensive Cancer Center and Dr. Eric Raabe, M.D., Ph.D. focused on Lantern's drug candidate LP-184 in the area of brain tumors, and specifically in Atypical Teratoid Rhabdoid Tumors (\"ATRT\"), an ultra-rare and fast-growing cancerous tumor of the brain that presents primarily in children. \n\n \n \n \n \n \n \n\n \n\"As we enriched our RADR® A.I. platform for additional cancer indications, we began to discover common molecular pathways that drive response to our drug candidate, LP-184, across multiple additional CNS cancers,\" stated Panna Sharma, President and CEO of Lantern Pharma. \"Chief among these newly identified CNS cancers was ATRT, an ultra-rare and fast-growing cancerous tumor of the brain that presents primarily in children with no effective therapies. The urgency of directing LP-184 towards helping children battle this particularly aggressive cancer was self-evident, as was the opportunity to collaborate with the Johns Hopkins' pediatric oncologist, Dr. Eric Raabe, who has devoted his career to studying pediatric brain cancers, including ATRT.\"\nRhabdoid tumors (RTs) can emerge in the brain, kidneys, liver and all compartments of the central nervous system (\"CNS\"). Approximately 66% of RTs occur in the CNS and are called ATRTs. ATRTs predominantly affect infants and young children, with up to 15% of ATRTs arising in the brain. Incidence of ATRT is between 1.4 and 3.0 per million, and the survival rate is between 10% and 15% depending on the age at diagnosis. Pediatric brain cancer is the second-leading cause of pediatric cancer death with the incidence rate growing at ~2.7% per year in the United States. \nDr. Eric Raabe, M.D., Ph.D., is assistant professor of oncology in the Divisi...